TRVN Trevena Inc.

1.77
+0.03  (1%)
Previous Close 1.74
Open 1.77
Price To book 2.35
Market Cap 109961231
Shares 62,300,981
Volume 52,712
Short Ratio 4.02
Av. Daily Volume 834,032

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 APOLLO-1 and APOLLO-2 data released February 21, 2017 - primary endpoints met. NDA filing announced November 2, 2017.
Oliceridine (TRV130)
Moderate to severe acute pain
Phase 2b endpoints not met - May 2016
TRV027 - BLAST-AHF
Acute heart failure

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171181236
  2. 8-K - Current report 171181067
  3. 8-K - Current report 171135617
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171019940
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171002962
  6. 8-K - Current report 171002766
  7. 8-K - Current report 17916282
  8. 8-K - Current report 17857780
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814340
  10. 8-K - Current report 17811762